Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

37.61 -0.56 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple... 
Via Benzinga
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday. SKLZ shares closed 9% lower... 
Via Benzinga
India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for... 
Via Benzinga
Exposures COVID-19
Cathie Wood Loaded Up Further On Skillz On Earnings Day
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $52.1 million, in Skillz Inc (NYSE: SKLZ) ahead of the mobile gaming company’s first-... 
Via Benzinga
Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD — Also Adds Skillz
Cathie Wood-led Ark Investment Management on Monday bought more shares of Pinduoduo Inc (NASDAQ: PDD) and JD.com Inc (NASDAQ: JD) — rivals to Alibaba Group Holding (... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
Via FinancialNewsMedia
Topics Death
Exposures Death
Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks
It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap... 
Via Talk Markets
Exposures COVID-19
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
Another Heavy News Day
For whatever it is worth, markets seem keen on the proposed measures, boosted by a nicely lower level of new unemployment insurance claims last week. 
Via Talk Markets
Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer
The FDA’s Oncologic Drugs Advisory Committee voted 5-3 in favor of keeping Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) accelerated approval... 
Via Benzinga
Exposures Product Safety
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in... 
Via Benzinga
Exposures COVID-19
A Heavy News Day And Crypto
Israeli TEVA reported Q1 sales which missed forecasts at $4 bn, leading to a 2.6% drop in its price earlier today. 
Via Talk Markets
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for Previously Untreated Metastatic Bladder Cancer
From Genentech
Via Business Wire
FDA Oncology Adcomm Votes To Keep Conditional Approval For Roche's Tecentriq In Place For Now
The FDA kicked off a three-day meet to reexamine the accelerated approvals of immuno-oncology drugs with confirmatory trials that have not met their primary endpoint(s) and have... 
Via Benzinga
Exposures Product Safety
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
From Genentech
Via Business Wire
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Tuesday Market Report
Swiss ABB gained 0.8% more today after it reported on its Q1 today, confirming the pre-announced data from earlier in April. 
Via Talk Markets
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
Disruptor Alert: These 2 Companies Are Changing Cancer Care
Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers. 
Via The Motley Fool
Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive Opinion
European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Roche Holdings AG’s (... 
Via Benzinga
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Earth Day
Once again the exchanges are unsure if they want to go up or down. 
Via Talk Markets
Cathie Wood Loads Up Heavily On Debutant Uipath, Trims Tesla
Cathie Wood-led Ark Investment Management on Wednesday snapped up millions of shares of the New York-based software automation company UiPath Inc (NYSE: PATH) on the day that it... 
Via Benzinga
Gold Is Back
Wednesday was another mixed day with oil stocks and foreign telcos up from demand rising--but US telcos going their own ways, with AT&T up, and Verizon down because it lost wireless subs. 
Via Talk Markets
Roche Backs 2021 Outlook Despite Lackluster Q1 Performance In Pharmaceuticals Division
Roche Holdings AG (OCTMKTS: RHHBY) posted Q1 sales of CHF 14.9 billion, up 3% Y/Y on a constant currency basis and down 1% on a reported basis. Sales in the... 
Via Benzinga
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
Cathie Wood Loads Up On DraftKings, Coinbase, Palantir, Sells Nvidia, Square
Cathie Wood-led Ark Investment Management on Tuesday snapped up another 236,348 shares of cryptocurrency exchange Coinbase Global... 
Via Benzinga
Cathie Wood Buys Peloton, Coinbase Dips, Cuts Nvidia Stake
Cathie Wood-led Ark Investment Management on Monday snapped up shares of the exercise bike maker Peloton Interactive Inc (NASDAQ: 
Via Benzinga
Currency Manipulation
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53. 
Via Talk Markets
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.